MedPath

Invex Therapeutics Ltd.

Invex Therapeutics Ltd. logo
🇦🇺Australia
Ownership
Public
Established
2019-01-01
Employees
1
Market Cap
-
Website
http://www.invextherapeutics.com

Clinical Trials

3

Active:2
Completed:0

Trial Phases

2 Phases

Phase 1:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 3
1 (33.3%)

A Trial to Determine the Efficacy and Safety of Presendin in IIH

Phase 3
Terminated
Conditions
Idiopathic Intracranial Hypertension
Interventions
Drug: Placebo
Drug: Presendin
First Posted Date
2022-04-26
Last Posted Date
2024-04-24
Lead Sponsor
Invex Therapeutics Ltd.
Target Recruit Count
14
Registration Number
NCT05347147
Locations
🇺🇸

UCHealth Sue Anschutz-Rodgers Eye Center - Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

University of Miami Leonard M. Miller School of Medicine (UMMSM) - Bascom Palmer Eye Institute, Miami, Florida, United States

🇺🇸

University of Minnesota Health, Minneapolis, Minnesota, United States

and more 21 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath